CCMG practice guideline: laboratory guidelines for next-generation sequencing.


Journal

Journal of medical genetics
ISSN: 1468-6244
Titre abrégé: J Med Genet
Pays: England
ID NLM: 2985087R

Informations de publication

Date de publication:
12 2019
Historique:
received: 15 03 2019
revised: 23 05 2019
accepted: 24 05 2019
pubmed: 14 7 2019
medline: 1 7 2020
entrez: 14 7 2019
Statut: ppublish

Résumé

PurposeThe purpose of this document is to provide guidance for the use of next-generation sequencing (NGS, also known as massively parallel sequencing or MPS) in Canadian clinical genetic laboratories for detection of genetic variants in genomic DNA and mitochondrial DNA for inherited disorders, as well as somatic variants in tumour DNA for acquired cancers. They are intended for Canadian clinical laboratories engaged in developing, validating and using NGS methods. METHODS OF STATEMENT DEVELOPMENT: The document was drafted by the Canadian College of Medical Geneticists (CCMG) Ad Hoc Working Group on NGS Guidelines to make recommendations relevant to NGS. The statement was circulated for comment to the CCMG Laboratory Practice and Clinical Practice committees, and to the CCMG membership. Following incorporation of feedback, the document was approved by the CCMG Board of Directors. DISCLAIMER: The CCMG is a Canadian organisation responsible for certifying medical geneticists and clinical laboratory geneticists, and for establishing professional and ethical standards for clinical genetics services in Canada. The current CCMG Practice Guidelines were developed as a resource for clinical laboratories in Canada and should not be considered to be inclusive of all information laboratories should consider in the validation and use of NGS for a clinical laboratory service.

Identifiants

pubmed: 31300550
pii: jmedgenet-2019-106152
doi: 10.1136/jmedgenet-2019-106152
pmc: PMC6929709
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

792-800

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Genet Med. 2011 Jul;13(7):676-9
pubmed: 21681105
J Mol Diagn. 2019 Mar;21(2):318-329
pubmed: 30610921
Nucleic Acids Res. 2010 Apr;38(6):1767-71
pubmed: 20015970
Nat Rev Genet. 2016 May 17;17(6):333-51
pubmed: 27184599
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Clin Oncol. 2015 Nov 1;33(31):3660-7
pubmed: 26324357
Eur J Hum Genet. 2016 Jan;24(1):2-5
pubmed: 26508566
Int J Mol Sci. 2017 Feb 15;18(2):
pubmed: 28212287
Eur J Hum Genet. 2010 Dec;18(12):1276-88
pubmed: 20664632
J Mol Diagn. 2017 May;19(3):341-365
pubmed: 28341590
J Mol Diagn. 2018 Jan;20(1):4-27
pubmed: 29154853
J Mol Diagn. 2014 Jan;16(1):89-105
pubmed: 24211365
BMC Bioinformatics. 2014 Jul 19;15:247
pubmed: 25038816
Genet Med. 2019 Jun;21(6):1267-1270
pubmed: 31015575
Nat Methods. 2016 Sep;13(9):784-91
pubmed: 27502217
J Mol Diagn. 2016 May;18(3):336-349
pubmed: 27105923
Bioinformatics. 2011 Aug 1;27(15):2156-8
pubmed: 21653522
Genet Med. 2013 Sep;15(9):733-47
pubmed: 23887774
J Med Genet. 2015 Jul;52(7):431-7
pubmed: 25951830
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Sci Data. 2016 Jun 07;3:160025
pubmed: 27271295
Genome Med. 2013 Sep 27;5(9):89
pubmed: 24070238
Genet Med. 2016 Feb;18(2):128-36
pubmed: 25880439
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Arch Pathol Lab Med. 2015 Apr;139(4):481-93
pubmed: 25152313

Auteurs

Stacey Hume (S)

Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada.

Tanya N Nelson (TN)

Department of Pathology and Laboratory Medicine, BC Children's Hospital, Vancouver, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.

Marsha Speevak (M)

Department of Laboratory Medicine and Genetics, Trillium Health Partners, Mississauga, Ontario, Canada.

Elizabeth McCready (E)

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.

Ron Agatep (R)

Department of Biochemistry and Molecular Genetics, University of Manitoba, Winnipeg, Manitoba, Canada.
Genomics Laboratory, Shared Health Diagnostic Services, Winnipeg, Manitoba, Canada.

Harriet Feilotter (H)

Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.

Jillian Parboosingh (J)

Department of Medical Genetics, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Research Institute, Alberta Children's Hospital, Calgary, Alberta, Canada.

Dimitri J Stavropoulos (DJ)

Department of Paediatric Laboratory Medicine, Genome Diagnostics, Hospital for Sick Children, Toronto, Ontario, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.

Sherryl Taylor (S)

Department of Medical Genetics, University of Alberta, Edmonton, Alberta, Canada.

Tracy L Stockley (TL)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada tracy.stockley@uhn.ca.
Department of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH